Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable

Seminars in Oncology

Volumn 44, Issue 2, 2017, Pages 132-135

  Prasad, Vinay ^a,b   Kaestner, Victoria ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Drug manufacturing; Me too drugs; Nivolumab; Pembrolizumab

Indexed keywords

NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; HUMAN; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RENAL CELL CARCINOMA; REVIEW; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MELANOMA; NEOPLASMS; SECONDARY; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MELANOMA; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVAL RATE;

EID: 85028355340     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2017.06.007     Document Type: Review

References (29)

1. Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
2. Ribas, A., Tumor immunotherapy directed at PD-1. N Engl J Med 366:26 (2012), 2517–2519.
3. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:26 (2012), 2443–2454.
4. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
5. London, S., Pembrolizumab-ipilimumab combo is highly active in advanced melanoma. Dermatology News, 2016 Available at: http://www.mdedge.com/edermatologynews/article/110395/melanoma/pembrolizumab-ipilimumab-combo-highly-active-advanced.
6. Kelsall, C., Pembrolizumab plus ipilimumab safe, effective for advanced melanoma. Perspective, 2016 Available at: http://www.healio.com/hematology-oncology/melanoma-skin-cancer/news/online/%7Bcdd6fd97-0007-4195-aac2-127abb0729d6%7D/pembrolizumab-plus-ipilimumab-safe-effective-for-advanced-melanoma.
7. Highlights of prescribing information: Opdivo. US Food and Drug Administration, 2017, 61.
8. Bellmunt, J., de Wit, R., Vaughn, D.J., et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:11 (2017), 1015–1026.
9. Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:19 (2015), 1803–1813.
10. McKay, R.R., Choueiri, T.K., Emerging role of combination immunotherapy regimens in metastatic renal cell carcinoma. ASCO Annual Meeting, 2016 https://am.asco.org/daily-news/emerging-role-combination-immunotherapy-regimens-metastatic-renal-cell-carcinoma.
11. Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375:19 (2016), 1823–1833.
12. Appraisal consultation document: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. Excellence NIFHAC, 2017, 1–29.
13. Montori, V.M., Devereaux, P.J., Adhikari, N.K., et al. Randomized trials stopped early for benefit: a systematic review. JAMA 294:17 (2005), 2203–2209.
14. Inman, S., Nivolumab misses PFS endpoint in frontline phase III NSCLC study. OncLive, 2016 Available at: http://www.onclive.com/web-exclusives/frontline-nivolumab-misses-pfs-endpoint-in-phase-iii-nsclc-study.
15. Bankhead, C., Nivolumab falls short in front-line NSCLC—platinum chemotherapy prevails in randomized trial, 2016 Available at http://www.medpagetoday.com/meetingcoverage/esmo/60710.
16. Gay, N., Prasad, V., Few people actually benefit from ‘breakthrough’ cancer immunotherapy. STAT, 2017 First Opinion. Available at: https://www.statnews.com/2017/03/08/immunotherapy-cancer-breakthrough/.
17. Fojo, T., Mailankody, S., Lo, A., Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg 140:12 (2014), 1225–1236.
18. Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 373:2 (2015), 123–135.
19. Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC) [Video]. ASCO University, 2016.
20. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373:17 (2015), 1627–1639.
21. Herbst, RS., Baas, P., Kim, D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:10027 (2016), 1540–1550.
22. Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
23. Sharma, P., Retz, M., Siefker-Radtke, A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18:3 (2017), 312–322.
24. Brawley, L., With 20 agents, 803 trials, and 166,736 patient slots, is pharma investing too heavily in PD-1 drug development?. Cancer Lett, 42(37), 2016.
25. Menon, S., Shin, S., Dy, G., Advances in cancer immunotherapy in solid tumors. Cancers (Basel), 8(12), 2016.
26. Drug Information. 2012. Available at: http://apps.who.int/medicinedocs/documents/s19565en/s19565en.pdf.
27. Assessment report: Opdivo. European Medicines Agency; April 23, 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/003985/WC500189767.pdf.
28. Assessment Report: Keytruda. European Medicines Agency; May 21, 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Public_assessment_report/human/003820/WC500190992.pdf.
29. Keegan, P., Division Director Summary Review: Pembrolizumab. Center for Drug Evaluation and Research, 2014 Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000SumR.pdf.